NEW YORK, NY, TAMPA, FL, BATON ROUGE, LA, October 7, 2020 (GLOBE NEWSWIRE) – via NewMediaWire – Todos Medical Ltd. (OTCQB: TOMDF), an in vitro diagnostic company focused on the distribution of Comprehensive answers for COVID-19 detection and diagnosis, as well as the progression of blood tests for the early detection of cancer and Alzheimer’s disease Array announced today that it has signed an exclusive source agreement with the American cell laboratory company CLIA, Integrated Health LLC, in line with the MOTOPARA Foundation Mobile Biosafety Level 3. Builds evolved labs (“cell labs”) to deal with the global COVID-19 pandemic. Mobile labs are firstly capable of running 1000 PCR tests consistent with an 8-hour shift and would possibly upgrade to 3000 PCR tests consistent with an 8-hour shift when the procedure is well implemented, and can perform tests of Immediate Antigen and Immediate Antibody Testing as Screening Equipment as a component of comprehensive test protocols designed to test capacity and decrease positivity rates. MOTO + PARA expects to be able to increase production until the end of the fourth quarter of 2020.
“We have been working with Todos Medical for several months and have put in position the maximum complete set of verification responses that our organization wants to execute our cellular lab strategy well,” said Eric Canonico, CEO of the MOTOPARA Foundation. ready to address the vital need for cellular verification responses nationwide in order to securely open up American communities. Integrated Health has been incredibly cutting edge and has provided us with a U. S. National Mobile CLIA Laboratory Certificate. The U. S. environment, giving us the flexibility to stick to science as COVID-19 controls evolve over the months. effects for immediate control at the COVID-19 site on a large scale, as well as controls for other respiratory diseases. This Mobile Labs network will load a key tool into our wa r opposite COVID-19 as the fall and winter months approach».
The MOTOPARA Foundation is a non-profit organization that coordinates well-trained retired veterans from all branches of the military that includes on-site operations, doctors, paramedics, and nurses to provide crisis relief solutions. MOTO PARA has designed its lab solution and cellular testing to provide comprehensive large-scale detection and monitoring solutions, diagnostic triage, and PCR confirmation tests to provide a comprehensive threat assessment that provides more data to resolution managers for imaginable threat assessment and action plans. Integrated Health guides the first cellular laboratory through CLIA lab validation, offering leadership and direction of laboratory policy and adherence to practices. MOTO PARA owns and operates cellular laboratories, vehicles, ships and aircraft, as well as the technical, physical and logistical staff of workers necessary to administer safe tests and laboratory services.
“Working with MOTO PARA y Todos is a wonderful opportunity to implement our CLIA cellular lab capabilities,” said Jeff Facheaux, CEO of Integrated Health. “We are fortunate to be well placed in the CLIA Lab mobile app and are excited to validate and prepare for the expansion of our Mobile Labs methods, processes and procedures for sets that will begin to be implemented starting in October.
“We are very pleased to have helped build the first two cellular labs, the first of which is being recently validated by CLIA, and we are very happy to help build many more, as MOTO PARA can guarantee fully funded contracts for their implementation,” said Gerald Commissiong, president and CEO of Todos Medical. “While we anticipate our ability to have a significant effect on improving the quantity and quality of testing in the US, we anticipate our ability to have a significant effect on improving the quantity and quality of testing in the US. Usa, we believe that cellular labs that offer comprehensive services in Site Responses are in fact critical to controlling epidemics and ensuring the protection of various environments. Mobile labs are opening doors to vital probabilities that don’t exist lately in COVID-19 testing. »
For more information on Todos Medical’s COVID-19 testing capabilities, visit www. todoscovid19. com
For EPI requests, please send an email to sales@todosmedical. com.
About MOTOPARA Foundation, Inc.
MOTOPARA Foundation, Inc. dba MOTOPARA Foundation ™, MOTOPARA ™ and MOTO PARA ™ is located in Tampa, Florida, USA, as a non-profit corporation incorporated in 2010 as 501 (c) (3), a foundation of Private non-profit (POF) operation under the U. S. Internal Revenue Code. The MOTOPARA Foundation is a non-governmental organization (NGO) committed to research, development, schooling, and the implementation of mobility logistics for Global Disaster First Response ™, and healthy and sustainable lives similar to science, technology, engineering, arts and mathematics, and the career that encompasses those sustainable and renewable resources both nationally and internationally.
MOTO PARA ™ is a neutral, non-partisan NGO that provides an elite asset-based mobility and logistics solution for search and rescue (SAR), reconnaissance (RECON), crisis reaction and humanitarian assistance. It is helping other NGOs, government agencies and foreign countries respond temporarily and safely by sending personnel, materials and people suffering from emergencies and crises. MOTO PARA employs full-time Special Forces veterans and Special Forces logistics veterans who carry out mission-critical interventions using the extensive education and joy gained during their military service. MOTO PARA intervenes by air, sea and land to succeed in the “zero point” of a crisis around the world, employing devices to transparent roads and travel to crisis sites while offering coordinated communications, electricity, water and coverage support.
MOTO PARA’s COVID-19 reaction is from its Biological Response and Protection Services division, which can serve countries around the world with its high-complexity cellular laboratories built to BSL-3 specifications, developed in conjunction with Integrated Health LLC.
www. motopara. org
About Integrated Health LLC
Integrated Health LLC, founded in Baton Rouge, Louisiana, USA, is a healthcare company with a department of cellular medical laboratories that is the first high-complexity CLIA-certified cellular laboratory built to the BSL-3 specification in the Western Hemisphere. Health specializes in ensuring that all communities have access to laboratory and analysis services, whether in urban, rural, or incredibly remote locations at home and abroad. wide variety of tests to meet the desires for diagnostic testing from any community.
www. integrated-health. com
About Todos Medical Ltd.
Headquartered in Rehovot, Israel, Todos Medical Ltd. (OTCQB: TOMDF) designs life-saving diagnostic responses for early detection of a variety of cancers. Patented biochemical infrared (TBIA) and corporate tests are a unique generation of cancer detection that uses peripheral blood research that provides an in-depth examination of the influence of cancer on the immune system, seeking biochemical adjustments in mononucleated blood and plasma cells. The two internal cancer screening controls evolved through All, TMB-1 and TMB-2, won the CE mark in Europe. Recently, Todos signed an exclusive option agreement to obtain the U. S. medical diagnostics company Provista Diagnostics, Inc. in order to obtain the rights of your qualified CLIA/CAP lab founded in Alpharetta, Georgia, and The Videssa® exclusive Advertising-level Blood Test provided. The transaction is expected to close in the third quarter of 2020
All also develop blood tests for early detection of neurodegenerative disorders, such as Alzheimer’s disease. Some diseases, adding Alzheimer’s disease, are believed to be the result of compromised mobile machinery that leads to the re-entry of the mobile cycle through neurons, leading to apoptosis. ElymPro is unique in the use of peripheral blood lymphocytes as a replacement for neural mobile function, suggesting unusual dating between PBL and brain neurons. In July 2020, Todos completed the acquisition of Breakthrough Diagnostics, Inc. , owner of the intellectual property of LymPro Test, Amarantus Bioscience Holdings, Inc. (OTC : AMBS).
In addition, Everyone has distribution agreements with corporations to distribute secure verification kits for the new coronavirus (COVID-19). The agreements cover several foreign suppliers of PCR verification kits and similar fabrics and materials, as well as antibody kits of various brands after completing Validation of such verification kits and materials at their CLIA/CAP qualified spouse lab in the United States. All have formed strategic partnerships with Integrated Health LLC, the MOTOPARA Foundation, to implement the COVID-19 cell check in the United States.
For more information, https://www. todosmedical. com/.
Forward-looking statements
Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used to discuss our clinical progression systems and planned clinical trials. These forward-looking statements are based solely on management’s existing expectations and are subject to significant dangers and uncertainties that may also cause actual effects to differ materially from those described in the forward-looking statements, adding hazards and uncertainties related to progress, time, burden and effects of clinical trials and product progression systems; difficulties or delays in downloading regulatory approval or patent coverage for candidate products; festival of other biogeneration companies; and our ability to offload the additional funding required to carry out our research, progression and commercialization activities. In addition, the following factors, among others, may also cause actual effects to differ materially from those described in the forward-looking statements: adjustments in generation requirements and market place; delays or obstacles in launching our clinical trials; adjustments in legislation; the lack of expansion and introduction of new technologies, products and programs in a timely manner; the lack of validation of our generation as we move forward and the lack of acceptance of our strategies throughout the clinical community; not retaining or attracting key workers whose wisdom is essential for the progression of our products; unforeseen clinical difficulties that could possibly expand with our process; loading of the final product higher than expected; loss of market place percentage and value stress resulting from the festival; and laboratory effects that do not translate into equally intelligent effects in real-world environments, all of which may also cause actual effects or functionality to differ materially from those considered in such forward-looking statements. Unless otherwise provided by law, Todos Medical assumes no legal responsibility to publicly publish any revisions to such forward-looking statements to reflect events or events near the date hereof or to reflect the occurrence of unforeseen events. For a more detailed description of the hazards and uncertainties affecting Todos Medical, please refer to its periodic reports with the United States Securities and Exchange Commission.
Contact with investors:
Kim Sutton Golodetz
LHA Investor Relations
Senior Vice President
(212) 838-3777
kgolodetz@lhai. com
Company Contact:
Priyanka Misra
All Medical
(917) 983-4229 ext. 103
priyanka@todosmedical. com
Media Contact:
Paula Angel-Jones
MOTOPARA Foundation
(813) 956-2458
paula. angel-jones@motopara. org
Attached file
TOMDF